Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

Veradermics' oral version of Rogaine led to "rapid and robust hair growth" for men with pattern hair loss. The recent IPO ...

In its SEC prospectus, Hemab says it intends to use the net proceeds, together with existing cash, to fund clinical ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating ...

Biotech mergers and acquisitions are accelerating, with $31.5 billion in deals in March 2026 alone, driven by an approaching $300 billion patent cliff by 2030. Large pharmaceutical companies are ...

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...